These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 20050904)

  • 21. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
    Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
    Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
    Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.
    Colloby SJ; Williams ED; Burn DJ; Lloyd JJ; McKeith IG; O'Brien JT
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1176-85. PubMed ID: 15931516
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relationship between striatal
    Sawada H; Orimo S
    Rinsho Shinkeigaku; 2019 Dec; 59(12):799-805. PubMed ID: 31761832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between [
    Ramani L; Malek N; Patterson J; Nissen T; Newman EJ
    Acta Neurol Scand; 2017 Apr; 135(4):400-406. PubMed ID: 27255673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease.
    Kaasinen V; Kinos M; Joutsa J; Seppänen M; Noponen T
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1931-7. PubMed ID: 24867256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine transporter availability in motor subtypes of de novo drug-naïve Parkinson's disease.
    Moccia M; Pappatà S; Picillo M; Erro R; Coda AR; Longo K; Vitale C; Amboni M; Brunetti A; Capo G; Salvatore M; Barone P; Pellecchia MT
    J Neurol; 2014 Nov; 261(11):2112-8. PubMed ID: 25119838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study.
    Verstappen CC; Bloem BR; Haaxma CA; Oyen WJ; Horstink MW
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):502-7. PubMed ID: 17053905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease.
    Eshuis SA; Maguire RP; Leenders KL; Jonkman S; Jager PL
    Eur J Nucl Med Mol Imaging; 2006 Feb; 33(2):200-9. PubMed ID: 16228235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected].
    Iranzo A; Lomeña F; Stockner H; Valldeoriola F; Vilaseca I; Salamero M; Molinuevo JL; Serradell M; Duch J; Pavía J; Gallego J; Seppi K; Högl B; Tolosa E; Poewe W; Santamaria J;
    Lancet Neurol; 2010 Nov; 9(11):1070-7. PubMed ID: 20846908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease.
    Covelli EM; Brunetti A; Di Lauro A; Sullo P; Mazzarella G; Tedeschi E; Belfiore G
    Radiol Med; 2004 Oct; 108(4):417-25. PubMed ID: 15525895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease.
    Booij J; Habraken JB; Bergmans P; Tissingh G; Winogrodzka A; Wolters EC; Janssen AG; Stoof JC; van Royen EA
    J Nucl Med; 1998 Nov; 39(11):1879-84. PubMed ID: 9829575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings.
    Gigante AF; Defazio G; Niccoli Asabella A; Superbo M; Ferrari C; Liuzzi D; Iliceto G; Livrea P; Rubini G
    Acta Neurol Scand; 2016 Oct; 134(4):265-70. PubMed ID: 26659996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations.
    Benamer HT; Oertel WH; Patterson J; Hadley DM; Pogarell O; Höffken H; Gerstner A; Grosset DG
    Mov Disord; 2003 Sep; 18(9):977-84. PubMed ID: 14502664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.
    Walker Z; Costa DC; Walker RW; Lee L; Livingston G; Jaros E; Perry R; McKeith I; Katona CL
    Neurology; 2004 May; 62(9):1568-72. PubMed ID: 15136683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 123I-FP-CIT brain SPECT (DaTSCAN) imaging in the diagnosis of patients with movement disorders--first results.
    Jauković L; Ilić TV; Dopudja M; Ajdinović B
    Vojnosanit Pregl; 2012 Feb; 69(2):157-62. PubMed ID: 22500370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.